Capital Impact Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Capital Impact Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,835	Closed	-$200K	–	254
2015 Q3	$200K	Hold	2,835	–	–	0.1%	239
2015 Q2	$315K	Hold	2,835	–	–	0.14%	231
2015 Q1	$267K	Sell	2,835 -984	-26%	-$110K	0.12%	249
2014 Q4	$428K	Buy	3,819 +3,815	+95,375%	+$341K	0.2%	82
2014 Q3	$234	Sell	4 -3,815	-100%	-$164K	﹤0.01%	92
2014 Q2	$175K	Buy	+3,819	New	+$156K	0.13%	116

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FV2GP

Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Impact Advisors's AGIO Position: Q4 2015 in Review

Capital Impact Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2015, closing a stake of 2,835 shares — an estimated $200K sold.

Capital Impact Advisors first reported a position in AGIO in Q2 2014 and held it in 6 quarters. The position peaked at $428K in Q4 2014. 145 funds tracked by Wall St. Rank hold AGIO as of Q4 2015.

Capital Impact Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Capital Impact Advisors sold 2,835 Agios Pharmaceuticals shares in Q4 2015, an estimated $200K.
Capital Impact Advisors first reported a position in Agios Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Capital Impact Advisors's Agios Pharmaceuticals position peaked at $428K in Q4 2014.
145 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.